Back to top
more

QIAGEN (QGEN)

(Real Time Quote from BATS)

$45.83 USD

45.83
84,213

+0.81 (1.80%)

Updated Sep 27, 2024 10:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

LabCorp (LH)-QIAGEN Form Alliance in In-Vitro Diagnostics

by Zacks Equity Research

LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.

QIAGEN Unveils Liquid Biopsy Workflows & Panels, Widens Suite

by Zacks Equity Research

QIAGEN (QGEN) is progressing well with its testing menu expansion strategy.

    Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

    by Zacks Equity Research

    Sector ETF report for PBE

    QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test

    by Zacks Equity Research

    QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.

    Why Is Qiagen (QGEN) Up 8.1% Since Last Earnings Report?

    by Zacks Equity Research

    Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Intuitive Surgical Gets FDA Nod for Ion Endoluminal System

    by Zacks Equity Research

    The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.

    Sweta Killa headshot

    Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

    by Sweta Killa

    Sector ETF report for PBE

    Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y

    by Zacks Equity Research

    Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.

    QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark

    by Zacks Equity Research

    QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.

    Qiagen (QGEN) Q4 Earnings Meet Estimates

    by Zacks Equity Research

    Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and -1.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands

    by Zacks Equity Research

    QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.

    QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales

    by Zacks Equity Research

    QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.

    Sweta Killa headshot

    Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

    by Sweta Killa

    Sector ETF report for PBE

    QIAGEN Partners With Novartis to Expand CDx Tests Suite

    by Zacks Equity Research

    QIAGEN (QGEN) progresses well with the strategy to expand through strategic collaborations. The latest tie up will boost the company's companion diagnostic portfolio.

    QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach

    by Zacks Equity Research

    The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.

    QIAGEN's New Offerings to Broaden Hematology Testing Suite

    by Zacks Equity Research

    QIAGEN (QGEN) continues to progress with test menu expansion.

    Qiagen (QGEN) Down 3.5% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Pacific Biosciences Offers Insights on Aedes aegypti Genome

    by Zacks Equity Research

    Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.

    Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y

    by Zacks Equity Research

    Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.

    Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences

    by Zacks Equity Research

    Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.

    QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q3

    by Zacks Equity Research

    QIAGEN's (QGEN) year-over-year revenue growth in Q3 and operating margin expansion are encouraging.

    Qiagen (QGEN) Q3 Earnings Surpass Estimates

    by Zacks Equity Research

    Qiagen (QGEN) delivered earnings and revenue surprises of 6.06% and -1.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

    Qiagen (QGEN) Q3 Earnings Preview: What to Look Out For

    by Zacks Equity Research

    Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite

    by Zacks Equity Research

    QIAGEN (QGEN) continues to expand test menu; latest European launch to boost portfolio and top line.